SCHEMBL2260966

SCHEMBL2260966

Fc1cc2ccoc2cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
NFKB1 P19838 1/20 0.45
MAOA P21397 1/20 0.45
ACHE P22303 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
IDO1 P14902 4/20 0.41
DYRK1A Q13627 4/20 0.39
CDK9 P50750 1/20 0.38
CTNNB1 P35222 1/20 0.38
WNT3A P56704 1/20 0.38
EPM2A O95278 1/20 0.38
PTPRC P08575 1/20 0.38
PTPN6 P29350 1/20 0.38
CDC14A Q9UNH5 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649528 0.84 CYP2A6 (0.41) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL18876066 0.82 CYP2A6 (0.40) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL16048196 0.82 IDO1 (0.44) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL5987181 0.82 IDO1 (0.44) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL25082068 0.82 CYP2A6 (0.40) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL24138808 0.82 IDO1 (0.43) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL6951917 0.82 CYP2A6 (0.40) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL6921640 0.82 IDO1 (0.43) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL2149910 0.81 CYP2A6 (0.54) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9
SCHEMBL20858649 0.79 IDO1 (0.46) CYP2A6KDM4ECYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403482-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2021-12-30 US disclosed
EP-2922845-B1 ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF MERIAL INC (US) 2018-06-20 EP disclosed
US-8058425-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-11-15 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
US-7491716-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2009-02-17 US disclosed
US-20050090483-A1 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090483-A1 Purine derivatives as kinase inhibitors PNP, ADK, NME2 CYP2A6 2565/4885KDM4E 1308/4885CYP3A4 2350/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 CYP2A6 2565/4885KDM4E 1308/4885CYP3A4 2350/4885
US-20210403482-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 CYP2A6 3564/4885KDM4E 4765/4885CYP3A4 3182/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 CYP2A6 2565/4885KDM4E 1308/4885CYP3A4 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.